Opening New Frontiers in Cancer Treatment
Accuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk
Treating Rare Cancers with a Novel Platform
Targeting drugs to the σ-2 receptor is one of the most attractive cancer drug targeting strategies yet discovered. Accuronix’s expertise in σ-2 will drive an expansion of our library of receptor ligands that can deliver multiple anti-cancer “warheads” to tumor cells.
ACXT-3102 is a novel small molecule drug conjugate in preclinical development for pancreatic adenocarcinoma, synovial sarcoma, and other rare tumors. It employs Accuronix’s σ-2 technology to deliver a warhead that kills tumor cells by promoting both apoptosis and ferroptosis, a newly recognized pathway for cancer cell death.
The substantial unmet needs in pancreatic cancer, coupled with the potential of ACXT-3102 in additional oncology indications, affords promising opportunities to achieve fast track and breakthrough designations. We will pursue development of this candidate as well as follow-on opportunities through partnerships.